Literature DB >> 15698392

Cognition in liver disease.

Alexander Collie1.   

Abstract

BACKGROUND: Cognitive dysfunction has been observed in a range of liver diseases including chronic hepatitis C virus, alcoholic liver disease, primary biliary cirrhosis and Wilson's disease. Such dysfunction may range from mild cognitive changes to overt hepatic encephalopathy, and represents a significant complication of liver disease that may negatively impact the patient's quality of life, and normal activities of daily living (e.g., driving).
METHOD: This article reviews the published evidence relating to cognitive dysfunction in liver disease. OUTCOME: Issues of definition, diagnosis, epidemiology, aetiology, treatment and outcome are discussed. Particular attention is devoted to identifying the mild cognitive changes that occur in liver diseases of different aetiology.

Entities:  

Mesh:

Year:  2005        PMID: 15698392     DOI: 10.1111/j.1478-3231.2005.01012.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  13 in total

1.  Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study.

Authors:  Galit Weinstein; Kendra Davis-Plourde; Jayandra J Himali; Shira Zelber-Sagi; Alexa S Beiser; Sudha Seshadri
Journal:  Liver Int       Date:  2019-06-26       Impact factor: 5.828

Review 2.  Palliative care for patients with end-stage liver disease.

Authors:  Anne M Larson
Journal:  Curr Gastroenterol Rep       Date:  2015-05

Review 3.  Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease.

Authors:  Giuseppe Astarita; Daniele Piomelli
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-05-04       Impact factor: 4.006

Review 4.  Neuropsychological aspects of liver disease and its treatment.

Authors:  R E O'Carroll
Journal:  Neurochem Res       Date:  2007-10-24       Impact factor: 3.996

5.  Cognitive functioning in chronic acquired hepatocerebral degeneration.

Authors:  Andrea Stracciari; Katia Mattarozzi; Roberto D'Alessandro; Elisa Baldin; Maria Guarino
Journal:  Metab Brain Dis       Date:  2008-04-24       Impact factor: 3.584

6.  The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder.

Authors:  Marilyn Huckans; Adriana Seelye; Tiffany Parcel; Lisa Mull; Jonathan Woodhouse; Danell Bjornson; Bret E Fuller; Jennifer M Loftis; Benjamin J Morasco; Anna W Sasaki; Daniel Storzbach; Peter Hauser
Journal:  J Int Neuropsychol Soc       Date:  2009-01       Impact factor: 2.892

Review 7.  Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.

Authors:  Samantha J Mayo; Maryam Lustberg; Haryana M Dhillon; Zev M Nakamura; Deborah H Allen; Diane Von Ah; Michelle C Janelsins; Alexandre Chan; Karin Olson; Chia Jie Tan; Yi Long Toh; Jeong Oh; Lisa Grech; Yin Ting Cheung; Ishwaria Mohan Subbiah; Duska Petranovic; James D'Olimpio; Margherita Gobbo; Susanne Koeppen; Charles L Loprinzi; Linda Pang; Shivani Shinde; Olanipekun Ntukidem; Katherine B Peters
Journal:  Support Care Cancer       Date:  2020-11-24       Impact factor: 3.603

Review 8.  Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?

Authors:  Anna Czarnecka; Krzysztof Milewski; Magdalena Zielińska
Journal:  Neurochem Res       Date:  2016-11-25       Impact factor: 3.996

9.  Quality of life in Wilson's disease.

Authors:  R N Komal Kumar; A B Taly; K P S Nair; S Sinha; L K Prashanth; N Vidya; G R Arunodaya; S Rao
Journal:  Ann Indian Acad Neurol       Date:  2008-01       Impact factor: 1.383

10.  Combined Intraperitoneal and Intrathecal Etanercept Reduce Increased Brain Tumor Necrosis Factor-Alpha and Asymmetric Dimethylarginine Levels and Rescues Spatial Deficits in Young Rats after Bile Duct Ligation.

Authors:  Jiunn-Ming Sheen; Yu-Chieh Chen; Mei-Hsin Hsu; You-Lin Tain; Hong-Ren Yu; Li-Tung Huang
Journal:  Front Cell Neurosci       Date:  2016-06-23       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.